News
Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback